Helpline No. : 7599221100

Targeted Therapy

The drugs designed for specific targets (receptors) in and around cancer cells form the targeted therapy. In many cancers, the continuous cell proliferation is due to the overactivity of certain genes and hence their proteins. In targeted therapy, the activity of those particular genes and proteins is targeted so that the incessant cell proliferation does not take place. Due to the blockade of the particular pathway, dramatic results are achieved in certain cancers.

Examples

  • Imatinib, Dasatinib, Nilotinib, Bosutinib and Ponatinib inhibiting bcr-abl fusion protein in Chronic Myeloid Leukemia
  • Gefitinib, Erlotinib in EGFR mutant lung cancer
  • Crizotinib (Xalkori / Crizalk) in ALK-EML4 translocation positive lung cancer and Anaplastic Large Cell Lymphoma
  • Afatinib (Gilotrif) – EGFR and Her-2 inhibitor in EGFR exon 19 deletions or exon 21 substitution (L858R) in lung cancer
  • Sorafenib, Sunitinib, Pazopanib in Renal Cancer and Pancreatic Neuroendocrine Tumors
  • Axitinib (Inlyta) -- KIT, PDGFRβ, VEGFR 1/2/3 inhibitor in renal cell carcinoma
  • Regorafenib (Stivarga/ Nublexa) in colorectal cancer and Gastrointestinal Tumors (GIST)
  • Rituximab (Ristova) - anti CD 20 monoclonal antibody) for CD 20 +ve Lymphomas
  • Brentuximab vedotin (Adcetris) for anti CD 30 positive lymphomas (Hodgkin’s and Anaplastic large cell lymphoma)
  • Belinostat (Beleodaq) and Vorinostat (Zolinga) – HDAC inhibitors in peripheral T-cell lymphoma
  • Trastuzumab (Herceptin/Herclon) and Pertuzumab (Perjeta) -- anti Her-2-neu monoclonal antibodies for Her-2-Neu +ve breast cancers
  • Lapatinib (Tykerb) – anti Her-2-neu in Her-2-neu +ve breast cancer
  • Ado-Trastuzumab Emtansine / T-DM1 (Kadcyla) – antibody drug conjugate in breast cancer
  • Bevacizumab (Avastin)—monoclonal antibody against VEGF ligand for kidney, colorectal, glioblastoma, breast, lung, ovarian, cervix and endometrial cancers
  • Cetuximab (Erbitux) and Panitumumab (Vectibix) in K-RAS wild type colorectal cancer and lung cancer
  • Pembrolizumab (Keytruda), Nivolumab (Opdivo) (Anti PD1 monoclonal antibodies) in lung cancer, melanoma, head and neck cancer
  • Palbociclib (Ibrance) -inhibitor of CDK 4 and CDK6) in recurrent ER, PR +ve and Her-2 –ve breast cancer
  • Denosumab (Xgeva) – monoclonal antibody against RANK ligand) in osteoporosis and bone metastases
  • Bortezomib, Carfilzomib - proteasome inhibitors in multiple myeloma
  • Vemurafenib (Zelboraf) and dabrafenib (Tafinlar) in melanoma and BRAF mutation positive cancers
  • Ipilimumab (Yervoy) – anti CTLA4 monoclonal antibody in melanoma
  • Ibrutinib (Imbruvica) – Bruton kinase inhibitor in mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstrom’s macroglobulinemia
  • Idelalisib (Zydelig) – PI3K inhibitor in chronic lymphocytic leukemia, follicular lymphoma and small cell lymphocytic lymphoma
  • Obinutuzumab (Gazyva) and Ofatumumab (Arzerra) – anti CD 20 monoclonal antibodies in chronic lymphocytic leukemia
  • Olaparib (Lynparza) in ovarian cancer with BRCA mutation
  • Cabozantinib (Cometriq) – FLT3, KIT, MET, RET, VEGFR2 inhibitor in medullary thyroid cancer and prostate cancer
  • Vandetanib (Caprelsa) – EGFR, RET and VEGFR2 inhibitor in medullary thyroid cancer
  • Lenvatinib (Lenvima) – anti VEGFR2 in thyroid cancer
  • Ibritumomab tiuxetan (Zevalin) anti CD 20 monoclonal antibody-drug conjugate in non-Hodgkin’s Lymphoma
  • Everolimus (Affinitor) and Temsorilimus (Torisel) – mTOR inhibitors in renal cell cancer, breast cancer
  • Ceritinib (Zykadia) in ALK-EML4 translocation positive lung cancer refractory to Crizotinib
  • Panobinostat (Farydak) – HDAC inhibitor in multiple myeloma
  • Ramucirumab (Cyramza) – monoclonal antibody against VEGFR2 in gastric or gastroesophageal carcinoma and non small cell lung cancer
  • Romidepsin (Istodax) – HDAC inhibitor in cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL)
  • Ruxolitinib (Jakafi) – JAK 1 and 2 inhibitor in myelofibrosis
  • Siltuximab (Sylvant) – monoclonal antibody against IL-6 in Castleman’s Disease
  • Sonidegib (Odomzo) smoothened inhibitor in basal cell carcinoma
  • Tocilizumab (Actemra) – against IL-6R in rheumatoid arthritis and being studied in some cancers
  • Tofacitinib (Xeljanz) – JAK 3 inhibitor in rheumatoid arthritis and being studied in some cancers
  • Vismodegib (Erivedge) – PTCH and smoothened inhibitor in basal cell carcinoma
  • Ziv-aflibercept (Zaltrap) – PIGF, VEGF A/B inhibitor in colorectal cancer